

Disclosures

Personal Commercial (17)

| Company Name | Relationship Category | Compensation Level | Topic Area(s) |
|---|--|--------------------------|--------------------------------------|
| <i>Self</i> | | | |
| AbbVie, Inc. | Data Safety Monitoring Board | Modest (< \$5,000) | <i>Other</i> |
| AlwithCare | Stock | None (\$0) | <i>Other</i> |
| Amgen Inc. | Research/Research Grants ‡ OCEAN(a) | Significant (>= \$5,000) | <i>General Cardiology</i> |
| Arboretum Bioscience | Stock | Modest (< \$5,000) | <i>Other</i> |
| AstraZeneca Pharmaceuticals | Data Safety Monitoring Board | Modest (< \$5,000) | |
| Boehringer Ingelheim Pharmaceuticals, Inc | Research/Research Grants | Significant (>= \$5,000) | <i>General Cardiology</i> |
| Boehringer Ingelheim Pharmaceuticals, Inc | Consultant Fees/Honoraria | Significant (>= \$5,000) | <i>Other</i> |
| Bristol-Myers Squibb Company | Consultant Fees/Honoraria | Modest (< \$5,000) | <i>General Cardiology</i> |
| Hanmi | Data Safety Monitoring Board | Modest (< \$5,000) | <i>General Cardiology</i> |
| Health [at] Scale | Ownership Interest/Partnership/Principal | Modest (< \$5,000) | <i>General Cardiology</i> |
| Lexeo | Data Safety Monitoring Board | Modest (< \$5,000) | <i>General Cardiology</i> |
| Merck & Co., Inc. | Research/Research Grants | Significant (>= \$5,000) | <i>General Cardiology</i> |
| Novo Nordisk Inc. | Research/Research Grants | Significant (>= \$5,000) | <i>General Cardiology</i> |
| Novo Nordisk Inc. | Consultant Fees/Honoraria | Significant (>= \$5,000) | <i>General Cardiology</i> |
| Pfizer Inc | Research/Research Grants | Significant (>= \$5,000) | <i>General Cardiology</i> |
| Verve Therapeutics | Consultant Fees/Honoraria | Modest (< \$5,000) | <i>Stable Ischemic Heart Disease</i> |
| <i>Spouse/Domestic Partner/Immediate Household Member</i> | | | |
| Vertex Pharmaceuticals | Salary | Significant (>= \$5,000) | <i>Other</i> |

Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

Personal Organizational or Other Non-Commercial (0)

No disclosures on record

Clinical Trial Enroller (0)

No disclosures on record

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (1)

| Year | Case Title | Represented | Description | Compensation |
|-------------|----------------------------------|-------------|-------------|--------------------------|
| <i>Self</i> | | | | |
| 2018 | Testosterone Replacement Therapy | Defendant | | Significant (>= \$5,000) |

‡ Commercial Funding Source | ‡ Trial Name

Agreement

Certified Education Attestation | Signed on 7/10/2025

URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>

Confidentiality, Disclosure and Assignment Agreement | Signed on 7/10/2025

URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>

Embargo | Signed on 7/10/2025

URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>

On-Going Obligation Agreement | Signed on 7/10/2025

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.